MK-0616 is smashing all competitors for the prevention and treatment of atherosclerosis.
Regeneron Pharmaceuticals
Posted inCOVID-19, Infections, Research
Omicron Treatment: Most Effective Drugs
Efficacy of antivirals and monoclonal antibodies for outpatient treatment of COVID-19 infection with the Omicron variant of SARS-CoV-2 coronavirus.
Posted inNew Drugs, Oncology, Rare/Orphan Diseases, Regulatory
Tecvayli: New Drug for Multiple Myeloma
Teclistamab by Johnson & Johnson is a new hope for refractory or relapsing multiple myeloma.
Posted inCOVID-19, Infections, New Drugs, Regulatory
Evusheld: First Drug for Strong and Long-Lasting Protection Against Coronavirus
One dose of AstraZeneca’s monoclonal antibody cocktail protects against COVID-19 for six months or longer.
Posted inNew Drugs, Regulatory
Vabysmo: New Drug for Wet Age-Related Macular Degeneration and Diabetic Macular Edema
Faricimab by Roche is a strong competitor to Eylea.
Posted inAutoimmune Diseases, New Drugs, Regulatory
Tezspire: Effective Treatment for Severe Uncontrolled Asthma
Tezepelumab is a powerful new drug for asthma, invented by Amgen and AstraZeneca, with a completely new mechanism of action.
Posted inCOVID-19, Infections, Research
Omicron Variant: Latest Scientific News, Findings, Evidence, and Developments
Up-to-date scientific information about the new Omicron variant of SARS-CoV-2/COVID-19.
